PCARE -Associated Retinopathy – Genetics, Clinical Characteristics, and Natural History
Investigative Ophthalmology & Visual Science · 2025-04-22 · 66 (4) · 61
DOI: 10.1167/iovs.66.4.61 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, published on 2025-04-22. Written by Lorenzo Bianco and 11 co-authors. Institution: Sorbonne Université, INSERM, CNRS, Institut de la Vision, Paris, France. Major MEDLINE topics: Mutation, Retinal Diseases. Cited 5 times so far (Crossref); 43 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Purpose
The purpose of this study was to describe the mutational landscape, clinical characteristics, and natural history of PCARE-associated retinopathy.
Methods
Retrospective cohort study including 28 patients (56 eyes) affected by an inherited retinal disease related to PCARE variants. The main outcome measures were best-corrected visual acuity (BCVA) and degree of vision impairment, kinetic visual field (KVF) area delimited with the V4e target, area of macular atrophy (MA) with definitely decreased autofluorescence (DDAF) on short-wavelength autofluorescence, total macular volume (TMV) and foveal sparing (FS) on optical coherence tomography.
Results
The median age at first examination was 40.7 years (Interquartile range [IQR] = 28.8-49.6), whereas the median follow-up time was 5.7 years (IQR = 3.6-7.1). The retinal phenotype was consistent with a severe generalized photoreceptor dystrophy with MA in all patients. DDAF lesions were observed in 85% of the eyes. Loss of FS (occurring at a median age of 45 years) was associated with a mean BCVA (logMAR) worsening by 1.1 (95% confidence interval [CI] = 0.6 to 1.5, P < 0.001). Low vision and blindness in the better-seeing eye occurred at median ages of 50 and 57 years, respectively. Longitudinal analysis revealed the following mean slopes of change: BCVA (logMAR) worsened by 0.06/year (95% CI = 0.03 to 0.09, P < 0.001), KVF area decreased by -23%/year (95% CI = -35% to -12%, P = 0.004), square root-transformed DDAF area expanded by 0.20 mm/year (95% CI = 0.16 to 0.23, P < 0.001), and TMV declined by -0.015 mm3/year (95% CI = -0.023 to -0.007, P = 0.003). Eleven novel PCARE variants were identified.
Conclusions
PCARE-associated retinopathy is a severe generalized photoreceptor dystrophy with MA. Although visual field loss occurs early, useful central vision is often retained into late adulthood because of FS. Based on the age of onset of legal blindness, the optimal therapeutic window appears to be before the fifth decade of life.
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- Sorbonne Université, INSERM, CNRS, Institut de la Vision, Paris, France.
- CHNO des Quinze-Vingts, Centre de Référence Maladies Rares REFERET and INSERM-DGOS CIC1423, Paris, France.
- Department of Ophthalmology, IRCCS San Raffaele Hospital, Milan, Italy.
- Department of Ophthalmology, The University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States.
Cite
APA
Bianco, L., Antropoli, A., Benadji, A., Atia, R., Palacci, O., Condroyer, C., Antonio, A., Navarro, J., Battaglia Parodi, M., Sahel, J. A., Zeitz, C., & Audo, I. (2025). PCARE -Associated Retinopathy – Genetics, Clinical Characteristics, and Natural History. Investigative Ophthalmology & Visual Science, 66(4), 61. https://doi.org/10.1167/iovs.66.4.61
Vancouver
Bianco L, Antropoli A, Benadji A, Atia R, Palacci O, Condroyer C, et al. PCARE -Associated Retinopathy – Genetics, Clinical Characteristics, and Natural History. Investigative Ophthalmology & Visual Science. 2025;66(4):61. doi:10.1167/iovs.66.4.61
BibTeX
@article{Bianco2025,
author = {Bianco, Lorenzo and Antropoli, Alessio and Benadji, Amine and Atia, Raphaël and Palacci, Oana and Condroyer, Christel and Antonio, Aline and Navarro, Julien and Battaglia Parodi, Maurizio and Sahel, José-Alain and Zeitz, Christina and Audo, Isabelle},
title = {PCARE -Associated Retinopathy – Genetics, Clinical Characteristics, and Natural History},
journal = {Investigative Ophthalmology & Visual Science},
year = {2025},
volume = {66},
number = {4},
pages = {61},
doi = {10.1167/iovs.66.4.61}
}
EUVIMED